Cost-Effectiveness Analysis of Xiyanping Injection (Andrographolide Sulfonate) for Treatment of Adult Community Acquired Pneumonia: A Retrospective, Propensity Score-Matched Cohort Study

<table class="fixed-width table-group" id="tab15"><tr><td><table class="table"><colgroup><col style="width:11.75em"/><col style="width:6.11em"/><col style="width:6.79em"/><col style="width:4.49em"/><col style="width:11.82em"/><col style="width:12.24em"/><col style="width:5.62em"/></colgroup><tr><td class="thead-hr" colspan="7"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">Cost (CNY)</td><td class="align_center">Effecti-veness</td><td class="align_center">C/E</td><td class="align_center">Δ Incremental cost (CNY)</td><td class="align_center">Δ Incremental effectiveness</td><td class="align_center">ICER</td></tr><tr><td class="thead-hr" colspan="7"><hr/></td></tr><tr><td class="align_left" colspan="7"><i>Hospitalization stay (day)</i></td></tr><tr><td class="align_left"> Xiyanping combination</td><td class="align_center">3,917</td><td class="align_center">5.88</td><td class="align_center">666.16</td><td class="align_center">-4,572.00</td><td class="align_center">-1.05</td><td class="align_center">dominated</td></tr><tr><td class="align_left"> Antiviral</td><td class="align_center">8,489</td><td class="align_center">6.93</td><td class="align_center">1,224.96</td><td class="align_center"> </td><td class="align_center"> </td><td class="align_center"> </td></tr><tr><td class="align_left" colspan="7"><span width=""><i>Cure rate (</i><svg height="8.90755pt" id="M3" style="vertical-align:-0.4021397pt" version="1.1" viewbox="-0.0498162 -8.50541 9.89925 8.90755" width="9.89925pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M660 631L632 654L139 -3L167 -27L660 631ZM379 497C379 569 347 635 269 635C161 635 92 510 92 410C92 339 126 273 202 273C309 273 379 398 379 497ZM312 527C312 469 285 303 207 303C165 303 160 353 160 392C160 454 190 605 264 605C304 605 312 565 312 527ZM707 212C707 284 675 350 597 350C490 350 420 224 420 124C420 53 454 -12 530 -12C637 -12 707 113 707 212ZM640 241C640 183 613 17 535 17C493 17 488 68 488 106C488 169 518 320 592 320C632 320 640 279 640 241Z"></path></g></svg><i>)</i></span></td></tr><tr><td class="align_left"> Xiyanping combination</td><td class="align_center">3,917</td><td class="align_center">23.3</td><td class="align_center">112.23</td><td class="align_center">-4,572.00</td><td class="align_center">11.60</td><td class="align_center">394.14</td></tr><tr><td class="align_left"> Antiviral</td><td class="align_center">8,489</td><td class="align_center">34.9</td><td class="align_center">364.33</td><td class="align_center"> </td><td class="align_center"> </td><td class="align_center"> </td></tr><tr class="table-tr"><td colspan="7"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Results of CEA: Xiyanping combination versus antiviral.</div>

Evidence-Based Complementary and Alternative Medicine

tab15

Table 15

Table 15: Cost-Effectiveness Analysis of Xiyanping Injection (Andrographolide Sulfonate) for Treatment of Adult Community Acquired Pneumonia: A Retrospective, Propensity Score-Matched Cohort Study 

Table 15 | Cost-Effectiveness Analysis of Xiyanping Injection (Andrographolide Sulfonate) for Treatment of Adult Community Acquired Pneumonia: A Retrospective, Propensity Score-Matched Cohort Study 